Clinilabs has been selected to conduct a Phase I study of an investigational medication for the treatment of Rosacea. Enrollment for this study is expected to begin in mid-September. Dr. Gary Zammit, president and chief executive officer of Clinilabs, said, “The award of this project represents a significant achievement for the organization as it builds upon its experience as a specialty service provider to expand into new therapeutic areas.”...